Halozyme Therapeutics, Inc. annual free cash flow for fiscal 2025 was $357 million, a decrease of 23.8% from $468 million in fiscal 2024. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Free Cash Flow | $357M | $468M | $373M | $235M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|---|---|
| Free Cash Flow | $176M | ($70M) | $176M | $98M | $153M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More HALO metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS
All HALO financial statements → Interactive HALO charts →
About TickerBase · Data methodology & sources